Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH

GRPHGraphite Bio, Inc. US flag

NASDAQ Global Market

3.18

USD

-0.09

- -

185.19MMarket Cap

Graphite Bio, Inc.

GRPH

(NASDAQ Global Market)

Recent

price

3.18

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Regeneus Ltd (RGS.AX)
PhaseRx, Inc. (PZRXQ)
Adocia S.A. (ADOCY)
Celyad Oncology S.A. (CLYYF)
NeuBase Therapeutics, Inc. (NBSE)
NanoLogix, Inc. (NNLX)
Business: Graphite Bio, Inc. (GRPH) operates as a clinical-stage biotechnology company transformed through its merger with LENZ Therapeutics, now focusing on the development and commercialization of ophthalmic solutions for presbyopia treatment; its primary product is VIZZ (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine-based eye drop targeting near vision loss in an estimated 128 million U.S. patients and 1.8 billion globally. The company leverages its pipeline of investigational therapies, previously centered on gene editing technologies via the proprietary Graphite Platform for precise DNA modifications in hematopoietic stem cells to address single-gene disorders including sickle cell disease (lead candidate GPH101 or nulabeglogene autogedtemcel), beta-thalassemia (GRPH-002), X-linked severe combined immunodeficiency, and Gaucher disease; these efforts have been discontinued post-merger to prioritize presbyopia assets. Founded in 2019 and headquartered in San Diego, California, with all long-lived assets in the United States, Graphite Bio serves the biotechnology and ophthalmology sectors targeting patients with serious genetic diseases and age-related vision impairment. In March 2024, Graphite Bio completed its merger with Lenz Therapeutics, accompanied by a $53.5 million private placement from investors including Versant Ventures, RA Capital Management, and RTW Investments, yielding approximately $210 million in cash for commercialization infrastructure; this transaction followed a special cash dividend to Graphite shareholders and a strategic pivot from gene editing programs, with LENZ advancing Phase 3 CLARITY trial topline results and NDA submission for LNZ100/LNZ101 presbyopia drops in mid-2024. The combined entity, trading under LENZ, maintains operations in the U.S. with no noted subsidiaries or parent relationships, emphasizing regulatory pathways and market expansion for VIZZ.

Company News